The Canadian cannabis producer Aphria Inc. announced on Tuesday, MAy 26th, that the company will be listed on the NASDAQ next week. To date, Aphria is traded on the TSX as well as the NYSE. Now the company plans to go to the NASDAQ on June 5th, the first trading day there is planned to be June 8th.
The CEO of Aphria, Irwin D. Simon said the move demonstrates the company’s commitment to cost-effective operations. Simon added that NASDAQ is a good fit for Aphria as it has made great strides in integrating ESG practices.
If you want to find more details about the situation in the cannabis market, how cannabis companies are trying to benefit from the current situation and to read the latest cannabis news, download the Hemp.im mobile app.
Cannabis sales increased in Canada
Statistics Canada reported last week that cannabis sales in the country increased significantly in March. The increase was 19.2% over February, with cannabis worth $132.4 million (CAD 182 million) sold.
The statisticians reported that this was the strongest monthly increase since cannabis legalization in October 2018. The strongest increase in sales was in Quebec, where it rose 29 percent. Sales also grew in Ontario, Alberta and British Columbia.
The Coronavirus pandemic and the lockdown in Canada drove customers to the points of sale, as many expected that stationary cannabis sales would also be discontinued. However, this has not happened.
The COVID-19 pandemic continues to dominate daily life in many countries around the world
Scientists, governments, companies and citizens are looking for ways to deal with the disease and mitigate its effects on the economy, while at the same time ensuring public health. A number of compounds are currently being tested for the treatment of COVID-19.
In Canada, scientists at the University of Lethbridge believe that there are cannabis extracts that could be used in the prevention and treatment of COVID-19. For example, cannabinoids could make the human body less susceptible to the novel coronavirus. Of course, in a lung disease such as COVID-19, drugs should not be absorbed through the lungs, but through edible products.
NeutriSci International plans to expand its business
Such edible cannabis products will be sold by NeutriSci International Inc. The company will soon bring such edible cannabis products to the shelves of more than 90 pharmacies in California. The local distributor plans to expand this to more than 350 pharmacies. NeutriSci International thus penetrates the largest cannabis market in North America. Marbl Melt is one of the products to be offered there – cannabis-added edible products enriched with THC or CBD in clinically tested doses.
This opens up huge sales opportunities for NeutriSci International. In the USA, $1 billion was spent on cannabis-based food and beverages in 2017. In 2022, a level of $4.1 billion should be reached there. Worldwide, the market for edibles could reach a volume of $32 billion, as expected by the Arcview Group.
In the next steps NeutriSci International plans to expand into the US states of Nevada, Oklahoma and Michigan. This year the expansion to Canada is also planned, where edible cannabis products have been legalized since October 2019.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in shareribs, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Why AI is set to become an integral part of every business
The value of the Artificial Intelligence global market extent was anticipated at $25.9 billion in the year 2018. It is...
Travel agencies resort to crowdfunding to survive the crisis
The Corona crisis has hit the travel agencies in the Neuenstadt region hard: instead of new bookings, cancellations are piling...
Coima launches ESG fund of urban regeneration, with a target over €1 bln
The Italian company Coima has recently launched an ESG fund, with the aim of investing in sustainable regeneration of the...
La Rioja, another Argentine province that wants to export cannabis
La Rioja province expressed its intention to become an important hub for cannabis exports. The Minister of Production and Environment,...
The Canary Islands government is seeking to attract African investments
The Canary Islands government aims to collaborate with the African continent from an economic and social point of view. The...
Business5 days ago
5 steps to help you build an eCommerce store
Featured6 days ago
The coronavirus favored the fintech sector and the digitization of Italian banks
Featured6 days ago
Why using ESG research in COVID-19 times is important
Biotech6 days ago
Apart from the rise of the Ibex35, pharma stocks fell by 2.7% in the second quarter